Hochman Cole Investment Advisors Inc. Purchases 3,084 Shares of Pfizer Inc. (PFE)
Hochman Cole Investment Advisors Inc. lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 30.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,064 shares of the biopharmaceutical company’s stock after purchasing an additional 3,084 shares during the quarter. Hochman Cole Investment Advisors Inc.’s holdings in Pfizer were worth $474,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Ballew Advisors Inc acquired a new stake in Pfizer in the 1st quarter valued at $102,000. Earnest Partners LLC acquired a new stake in Pfizer in the 4th quarter valued at $105,000. Woodard & Co. Asset Management Group Inc. ADV acquired a new stake in Pfizer in the 4th quarter valued at $118,000. Delpha Capital Management LLC acquired a new stake in Pfizer in the 4th quarter valued at $126,000. Finally, W.G. Shaheen & Associates DBA Whitney & Co acquired a new stake in Pfizer in the 1st quarter valued at $132,000. 69.12% of the stock is currently owned by institutional investors.
Several analysts recently commented on PFE shares. Credit Suisse Group set a $39.00 price target on Pfizer and gave the company a “hold” rating in a research note on Tuesday, July 31st. Goldman Sachs Group reissued a “neutral” rating and issued a $42.00 price objective on shares of Pfizer in a research note on Wednesday, August 1st. Societe Generale reissued a “neutral” rating and issued a $39.00 price objective on shares of Pfizer in a research note on Wednesday, May 30th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, July 31st. Finally, Cantor Fitzgerald began coverage on Pfizer in a research note on Thursday, June 7th. They issued an “overweight” rating and a $45.00 price objective on the stock. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $41.74.
PFE stock opened at $41.78 on Friday. The firm has a market cap of $249.13 billion, a PE ratio of 14.58, a PEG ratio of 2.01 and a beta of 0.96. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $42.77. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. The company had revenue of $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.67 earnings per share. equities research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 4th. Stockholders of record on Friday, August 3rd were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, August 2nd. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.26%. Pfizer’s payout ratio is currently 51.32%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Story: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.